2003 Drug Development Trials 
Drug Target Review
DECEMBER 14, 2023
She continued: “Now that we know more about this pathway, scientists could, in theory, produce a drug that could disrupt key pieces of the pathway in cancer cells, as opposed to using conventional chemotherapies that destroy healthy cells along with the cancer.” Dr Ramsden said: “Anytime you find new pieces of the pathway, you can ‘drug’ it.”
The Premier Consulting Blog
AUGUST 21, 2024
As clinical development of an investigational product proceeds, Sponsors often conduct global clinical trials which require preparation of content to support dossiers in multiple geographies, meeting the regulatory requirements of each region. QOS – optional Module 3.2.S
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
DECEMBER 15, 2020
Approval demonstrates our ability to execute upon the entirety of the drug development and registration process. Founded in 2003, Athenex, Inc. We are extremely proud of our team’s excellent execution,” said Dr. Johnson Lau, Chairman and Chief Executive Officer of Athenex. Total revenues in 2019 were 908.4 million euros.
PLOS: DNA Science
OCTOBER 17, 2024
The first-ever approval of a safe and effective drug option will undoubtedly support the essential medical needs of those suffering.” ” Miplyffa is the first drug developed to treat NPD3 specifically. The new drug is taken with miglustat , which FDA approved for use in NPD3 in 2009.
The Pharma Data
APRIL 25, 2021
Nirsevimab demonstrate d protect ion against respiratory syncytial virus disease in healthy infants in Phase 3 trial. The overall safety profile of nirsevimab in the trial remains consistent with previously reported results. Lurie Children’s Hospital of Chicago, Illinois, US and primary investigator of the MELODY Phase III trial.
NIH Director's Blog: Drug Development
MAY 21, 2020
In work described in the journal Nature , an international research team started with a set of neutralizing antibodies previously identified in a blood sample from a person who’d recovered from a different coronavirus-caused disease, called severe acute respiratory syndrome (SARS), in 2003 [3]. In the U.S.
NIH Director's Blog: Drug Development
MARCH 18, 2021
He’s also a member of the international research team that identified a human antibody, called S309, from a person who’d been infected with SARS in 2003. This antibody is showing promise for treating COVID-19 [3], now in a phase 3 clinical trial in the United States.
Expert insights. Personalized for you.
59 
Let's personalize your content